301. The association between low-density and non-high-density lipoprotein cholesterol with incident cardiovascular disease among low-risk Iranians during 2 decades follow-up
- Author
-
Maryam Tohidi, Samaneh Asgari, Abdolreza Chary, Fereidoun Azizi, and Farzad Hadaegh
- Subjects
Clinical Biochemistry ,General Medicine - Abstract
To examine the associations between low-density and non-high-density lipoprotein cholesterol (LDL-C and non-HDL-C, respectively) with incident cardiovascular disease (CVD) in low-risk subjects.From a total of 2467 non-diabetic aged 40-70 years, free of CVD with LDL-C range 1.81 ≤ LDL-C 4.91 mmol/L with 10-year atherosclerotic cardiovascular disease (ASCVD) risk7.5 %, the associations of LDL-C and non-HDL-C with incident CVD were assessed using multivariable Cox proportional hazard regression analyses adjusted for age, sex, body mass index, waist circumference, HDL-C, triglycerides, chronic kidney disease, current smoking, hypertension, and family history of CVD.During a median follow-up of 18 years, 559 CVD events occurred. Compared to the LDL-C 2.59 mmol/L as reference, the categories of 2.59 ≤ LDL-C 3.36, 3.36 ≤ LDL-C 4.14, and ≥ 4.14 mmol/L were associated with hazard ratios (95 % confidence intervals) of 1.39(0.89-2.18), 1.72(1.11-2.68), and 2.19(1.36-3.51) for incident CVD (P for trend0.0001), respectively. Compared to the non-HDL-C 3.36 as reference, the categories of 3.36 ≤ non-HDL-C 4.14, 4.14 ≤ non-HDL-C 4.91, and ≥ 4.91 mmol/L were associated with 1.48(0.96-2.30), 1.37(0.89-2.16), and 2.15(1.36-3.39) higher risk for incident CVD (P for trend = 0.001), respectively. Among those with ASCVD score5 % (n = 2070), even the 2.59 ≤ LDL-C 3.36 mmol/L increased the risk for CVD [1.73(1.01-2.97)]. Results for non-HDL-C categories remained unchanged compared to those with ASCVD risk7.5%.Among Iranian individuals with ASCVD risk as little as5 %, LDL-C ≥ 2.59 mmol/L and non-HDL-C ≥ 3.36 mmol/L, independent of traditional risk factors, were associated with a significantly higher risk of incident CVD, individuals that might potentially benefit from pharmacological therapy.
- Published
- 2022
- Full Text
- View/download PDF